This trial is testing the safety of a new immunotherapy drug for people with solid tumors. The drug will be given alone and in combination with another immunotherapy drug to see what the maximum tolerated dose is.
6 Primary · 28 Secondary · Reporting Duration: From first dose to first observation of documented disease progression (or death within 12 weeks of last tumor assessment) (up to 2 years)
Experimental Treatment
195 Total Participants · 3 Treatment Groups
Primary Treatment: AGEN1181 · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: